| LRP5 Protein |
|---|
| Protein Name | LDL Receptor-Related Protein 5 |
| Gene | LRP5 |
| Category | Protein |
| Path | /proteins/lrp5-protein |
LRP5 (Low-Density Lipoprotein Receptor-Related Protein 5) is a transmembrane receptor protein that plays critical roles in Wnt signaling, bone metabolism, and cholesterol homeostasis. As a co-receptor for Wnt ligands, LRP5 is essential for activating canonical Wnt/β-catenin signaling pathways that regulate embryonic development, adult tissue maintenance, and cellular functions in the brain. In the central nervous system, LRP5 is expressed in neurons, astrocytes, and microglia, where it modulates synaptic plasticity, cognitive function, and neuroprotection. Genetic variants in LRP5 have been associated with altered risk for Alzheimer's disease, osteoporosis, and metabolic disorders, making it an important therapeutic target [1][2].
LRP5 is a large type I transmembrane protein consisting of 1615 amino acids with the following domain organization:
- N-terminal extracellular domain: Contains four β-propeller motifs followed by three low-density lipoprotein receptor (LDLR) type A domains. These propeller domains mediate interactions with Wnt ligands and antagonists including Dkk1 and sclerostin [3].
- Single transmembrane helix: Spans the cell membrane, anchoring the receptor complex.
- C-terminal cytoplasmic tail: Contains PPXY motifs that interact with β-catenin destruction complex components and facilitate downstream signaling.
The protein forms heterodimers with Frizzled receptors to create functional Wnt receptor complexes. LRP5 can also undergo proteolytic cleavage, releasing its extracellular domain which may function as a decoy receptor [4].
LRP5 serves as a primary co-receptor for Wnt ligands in the canonical Wnt/β-catenin signaling pathway. Upon Wnt ligand binding to the LRP5-Frizzled receptor complex:
- Dishevelled (DVL) is recruited and phosphorylated
- β-catenin destruction complex (Axin, APC, GSK3β, CK1α) is inhibited
- Stabilized β-catenin translocates to the nucleus
- TCF/LEF transcription factors activate target gene expression
Target genes include:
- Cell cycle regulators (c-Myc, Cyclin D1)
- Osteogenic factors (Runx2, Osterix)
- Synaptic proteins (PSD-95, Synapsin)
- Anti-apoptotic proteins (Bcl-2, survivin) [5]
In osteoblasts, LRP5 activates Wnt signaling to:
- Promote osteoblast differentiation and survival
- Enhance bone formation
- Regulate osteoclast activity through RANKL/OPG signaling
Loss-of-function mutations cause osteoporosis-pseudoglioma syndrome (OPPG), while gain-of-function variants increase bone mass [6].
LRP5 influences lipid metabolism by:
- Regulating intestinal cholesterol absorption
- Modulating hepatic lipid homeostasis
- Influencing circulating LDL cholesterol levels
In the brain, LRP5 modulates:
- Synaptic plasticity: Regulates NMDA receptor trafficking and long-term potentiation (LTP)
- Cognitive function: Mouse models show impaired learning and memory with LRP5 deficiency
- Neuroprotection: Activates anti-apoptotic pathways and reduces oxidative stress
- Microglial function: Influences inflammatory responses in neurodegenerative contexts [7]
LRP5 plays a complex role in Alzheimer's disease pathogenesis:
Amyloid-β metabolism: LRP5 affects amyloid precursor protein (APP) processing through Wnt signaling modulation. Reduced LRP5 function may increase β-secretase (BACE1) activity, enhancing amyloidogenic APP cleavage [8].
Tau pathology: Wnt/β-catenin signaling normally suppresses GSK3β activity. LRP5 dysfunction may contribute to tau hyperphosphorylation through disinhibition of GSK3β [9].
Synaptic failure: LRP5 deficiency in neurons leads to:
- Reduced synaptic density
- Impaired LTP
- Decreased PSD-95 and Synapsin expression
- Memory deficits in mouse models
Genetic association: GWAS studies have identified LRP5 variants associated with:
- Late-onset Alzheimer's disease risk
- Age of onset modification
- Response to cholinesterase inhibitors [10]
Therapeutic implications: LRP5 agonists or Wnt pathway activators represent potential AD therapeutics. However, the blood-brain barrier penetration and peripheral effects remain challenges.
Autosomal recessive disorder caused by LRP5 loss-of-function mutations:
- Severe early-onset osteoporosis
- Blindness (pseudoglioma)
- Skeletal fragility
- Cognitive impairment in some cases
- Parkinson's disease: LRP5 variants may modify disease risk; role in dopaminergic neuron survival studied
- Multiple sclerosis: LRP5 influences immune cell trafficking and demyelination
- Stroke: LRP5-mediated neuroprotection against ischemic injury investigated [11]
- Wnt ligands: Recombinant Wnt proteins or stabilizers
- Small molecules: GSK3β inhibitors ( lithium, tideglusib)
- LRP5-binding compounds: Antibody fragments targeting propeller domains
- Dkk1 inhibitors: Neutralizing antibodies (DKN-01 in clinical trials)
- Sclerostin antibodies: Romosozumab approved for osteoporosis; brain penetration being explored
- Tissue-specific effects (bone vs. brain)
- Blood-brain barrier delivery
- Cancer risk with chronic Wnt activation
- Off-target effects on stem cell populations
LRP5 as a biomarker:
- Genetic: LRP5 polymorphisms predict AD risk and treatment response
- Expression: LRP5 mRNA in blood or CSF as potential biomarker
- Functional: Wnt signaling assays in patient-derived cells
- LRP5 in bone and brain (2021)
- LRP5 variants and Alzheimer's disease risk (2019)
- Structure of LRP5 extracellular domain (2020)
- LRP5 proteolytic cleavage and signaling (2018)
- Wnt/β-catenin in synaptic plasticity (2021)
- LRP5 mutations and bone metabolism (2020)
- LRP5 in neuroprotection (2022)
- LRP5 and amyloid-β metabolism (2019)
- Wnt signaling and tau pathology (2020)
- LRP5 GWAS in Alzheimer's disease (2018)
- LRP5 in stroke and neuroprotection (2021)